Latest Ratios: P/E Ratio -0.1x · EV/EBITDA N/A · ROE -0.1%. (2006–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $140M | $78M | $22M | — | — | — | — | — | — | — | — |
| Enterprise Value | $164M | $102M | $25M | — | — | — | — | — | — | — | — |
| P/E Ratio → | -0.13 | — | 2.44 | — | — | — | — | — | — | — | — |
| P/S Ratio | 325.25 | 181.35 | 161.77 | — | — | — | — | — | — | — | — |
| P/B Ratio | 0.00 | 0.00 | 0.28 | — | — | — | — | — | — | — | — |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 236.56 | 185.36 | — | — | — | — | — | — | — | — |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 76.8% | 76.8% | 4.4% | 3.6% | 53.8% | 48.0% | 33.3% | 65.5% | 88.3% | 100.0% | 99.3% |
| Operating Margin | -3763.8% | -3763.8% | -10758.7% | -322.4% | -28.4% | -53.5% | -14.6% | 1.7% | -2.3% | 13.5% | -40.6% |
| Net Profit Margin | -9618.0% | -9618.0% | 6634.7% | -1308.3% | -33.9% | -53.8% | -14.8% | -3.8% | 0.2% | 9.9% | -111.2% |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -0.1% | -0.1% | 22.8% | -4031.4% | -168.8% | -85.4% | -39.6% | -11.4% | 3.4% | — | — |
| ROA | -0.1% | -0.1% | 15.4% | -219.7% | -73.3% | -68.3% | -33.0% | -7.3% | 0.6% | 60.5% | -233.4% |
| ROIC | -0.0% | -0.0% | -24.6% | -81.0% | -160.3% | -150.3% | -66.5% | 6.1% | -13.3% | — | -165.2% |
| ROCE | -0.0% | -0.0% | -30.0% | -346.2% | -91.1% | -76.8% | -35.8% | 3.9% | -12.0% | 428.9% | — |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.00 | 0.00 | 0.04 | 12.47 | 4.62 | 0.33 | 0.07 | 0.24 | 1.00 | — | — |
| Debt / EBITDA | — | — | — | — | — | — | — | 4.54 | 12.68 | 1.49 | — |
| Net Debt / Equity | — | 0.00 | 0.04 | 12.47 | 1.43 | -0.50 | -0.61 | -0.45 | -0.03 | — | — |
| Net Debt / EBITDA | — | — | — | — | — | — | — | -8.52 | -0.38 | 1.08 | — |
| Debt / FCF | — | — | — | — | — | — | — | -31.48 | -0.10 | 2.81 | — |
| Interest Coverage | -9.66 | -9.66 | -13.06 | -6.42 | -6.15 | -224.34 | -85.29 | -4.34 | 1.16 | 2.84 | -6.74 |
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 2.89 | 2.89 | 0.80 | 0.24 | 0.98 | 4.72 | 10.95 | 7.30 | 1.70 | 1.16 | 0.23 |
| Quick Ratio | 2.82 | 2.82 | 0.80 | 0.24 | 0.94 | 4.66 | 9.46 | 7.19 | 1.61 | 1.16 | 0.23 |
| Cash Ratio | 0.00 | 0.00 | 0.04 | 0.00 | 0.51 | 3.37 | 7.03 | 5.51 | 1.01 | 0.35 | 0.01 |
| Asset Turnover | — | 0.00 | 0.00 | 0.11 | 2.76 | 1.72 | 1.75 | 1.33 | 1.72 | 4.75 | 7.36 |
| Inventory Turnover | 0.00 | 0.00 | — | 1358.26 | 72.20 | 91.39 | 9.08 | 45.20 | 5.62 | — | — |
| Days Sales Outstanding | — | 829882.42 | 14557.68 | 675.68 | 22.43 | 36.13 | 40.35 | 38.88 | 41.31 | 39.78 | 43.99 |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | 67.2% | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | 163.9% | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | 41.0% | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | — | — | — | — | — | — | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | 67.2% | — | — | — | — | — | — | — | — |
| Shares Outstanding | — | $153M | $4M | $2M | $564863 | $542449 | $513708 | $395272 | $388350 | $378736 | $350499 |
Persistent Operating Losses
According to recent market data, Scienture Holdings trades at a price-to-sales ratio of 339.09, a figure that appears disconnected from the company's underlying operational reality and suggests that investors are pricing in highly speculative future outcomes rather than current fundamental performance or tangible asset value.
The P/S multiple of 339.09 is exceptionally high, even when compared to the broader healthcare information services sector, indicating that the market may be assigning value based on potential future pivots rather than existing revenue streams. Given the negative TTM P/E and the absence of meaningful forward-looking earnings guidance, this valuation appears to rely heavily on sentiment rather than traditional fundamental support.
As reported in financial statements, Scienture Holdings has consistently generated negative returns on invested capital, with ROIC reaching -0.0% in 2026Q1 after a period of significant volatility, which highlights a persistent inability to deploy capital in a manner that creates value for shareholders.
The trend of negative ROIC over the last ten quarters suggests that the company is effectively destroying capital with every dollar invested into its operations. This decay is driven by the combination of recurring operating losses and an asset base heavily weighted toward goodwill, which provides no productive return on the capital allocated to it.
Based on the company's reported figures, the cash conversion cycle has exhibited extreme instability, swinging from a negative 999,999 days in 2025Q4 to 687,005 days in 2026Q1, which underscores profound challenges in managing operational efficiency and the timing of cash flows relative to business activity.
The wild fluctuations in the cash conversion cycle suggest that the company lacks a stable operational rhythm, likely due to inconsistent revenue recognition and irregular payment cycles. Such volatility makes it difficult to assess the company's true working capital efficiency, as the metrics appear more reflective of accounting anomalies than actual operational improvements.
As indicated by historical balance sheets, the current ratio has fluctuated wildly from a low of 0.11 in 2025Q2 to 1.70 in 2026Q1, reflecting a precarious liquidity profile that appears highly dependent on the timing of external capital infusions rather than stable operational cash flows.
The inconsistency in the current ratio suggests that the company's ability to meet short-term obligations is not supported by a predictable business model. Investors should monitor these liquidity swings closely, as the reliance on external financing to maintain even basic solvency levels poses a significant risk to the company's ongoing viability.
Based on the provided data, the price-to-sales ratio is the most commonly misapplied metric for Scienture Holdings, as it obscures the company's lack of a sustainable revenue base and ignores the massive dilution resulting from stock-based compensation and recurring capital raises.
Using P/S to value this business is misleading because it fails to account for the quality of revenue, which is currently negligible and highly volatile. A more appropriate focus would be on the cash burn rate and the path to positive free cash flow, as these metrics better capture the company's fundamental survival risk than a revenue-based multiple.
Includes 30+ ratios · 16 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying SCNX stock.
Scienture Holdings, Inc.'s current P/E ratio is -0.1x. The historical average is 2.4x.
Scienture Holdings, Inc.'s return on equity (ROE) is -0.1%. The historical average is -67.6%.
Based on historical data, Scienture Holdings, Inc. is trading at a P/E of -0.1x. Compare with industry peers and growth rates for a complete picture.
Scienture Holdings, Inc. has 76.8% gross margin and -3763.8% operating margin.